Showing 15,701 - 15,720 results of 105,548 for search '(( 50 ((nn decrease) OR (we decrease)) ) OR ( 5 ((a decrease) OR (mean decrease)) ))', query time: 1.01s Refine Results
  1. 15701
  2. 15702
  3. 15703
  4. 15704
  5. 15705

    Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Stud... by Ken Ohta (727449)

    Published 2015
    “…Commonly reported AEs with tiotropium 5 μg, 2.5 μg and placebo were nasopharyngitis (48.2%, 44.7%, 42.1%), asthma (28.9%, 29.8%, 38.6%), decreased PEFR (15.8%, 7.9%, 21.1%), bronchitis (9.6%, 13.2%, 7.0%), pharyngitis (7.9%, 13.2%, 3.5%) and gastroenteritis (10.5%, 3.5%, 5.3%). …”
  6. 15706

    AZ2.0 by Binay Panda (768771)

    Published 2015
    “…The updated genome assembly (v2.0) yielded 3- and 3.5-fold increase in N50 and N75, <br>respectively; 2.6-fold decrease in the total number of scaffolds; 1.25-fold increase in the number of <br>valid transcriptome alignments; 13.4-fold less mis-assembly and 1.85-fold increase in the <br>percentage repeat, resulted due to removal of mis-assembly and closure of gaps fromover the earlier <br>assembly (v1.0). …”
  7. 15707
  8. 15708
  9. 15709
  10. 15710
  11. 15711

    Risk of bias across 22 included studie. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  12. 15712

    An overview of the selection process for studies. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  13. 15713

    Characteristics of studies (<i>n</i> = 22). by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  14. 15714
  15. 15715
  16. 15716
  17. 15717
  18. 15718

    Nt5e is a trypsin-cleavable surface protein of <i>S. sanguinis</i> and affects platelet aggregation lag time. by Jingyuan Fan (159998)

    Published 2012
    “…All samples contained 15 µg of protein solubilized in 1% (w/v) SDS sample buffer. These samples were electrophoresed on a 10% gel, and stained with Coomassie Blue. …”
  19. 15719

    Integrin αVβ5 antibody inhibits the uptake of ROS by piPSC-RPE cells. by Jie Gong (339362)

    Published 2015
    “…Addition of an inhibitory anti-integrin αVβ5 antibody significantly decreased phagocytosis by approximately 50% in piPSC-RPE cells. …”
  20. 15720